Use of Angiotensin-(1-7) in COVID-19

Phase 1/2 Completed 112 enrolled Erasme University Hospital Angitec · collab Federal University of Minas Gerais · collab Fonds Erasme pour la Recherche Médicale · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.

Timeline

Start: 2020-08-05
Primary completion: 2021-11-01
Completion: 2021-11-01

Outcome

Missed primary endpoint

paper In Phase 2, OFDs did not differ between groups (median 19 [0-21] vs. 14 [0-18] days; p = 0.15). PMID 39231898 ↗

Publications

Martins ALV, Annoni F, da Silva FA, Bolais-Ramos L, de Oliveira GC, Ribeiro RC, Diniz MML, Silva TGF, Pinheiro BD, Rodrigues NA, Dos Santos Matos AH, Motta-Santos D, Campagnole-Santos MJ, Verano-Braga T, Taccone FS, Santos RAS. Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial. Ann Intensive Care. 2024 Sep 4;14(1):139. doi: 10.1186/s13613-024-01369-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	talfirastide	Peptide	10 ug/kg	Intravenous